Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?

Roviello, G. and Zanotti, L. and Cappelletti, M.R. and Gobbi, A. and Dester, M. and Paganini, G. and Pacifico, C. and Generali, D. and Roudi, R. (2018) Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clinical and Experimental Medicine, 18 (1). pp. 15-20.

Full text not available from this repository.
Official URL:


EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. However, not enough data are available on the efficacy of these targeted drugs in elderly patients. The aim of this study is to analyse the available clinical data evaluating the efficacy of anti-EGFR therapies in elderly patients with advanced NSCLC carrying EGFR mutations. A literature-based meta-analysis of the results of randomized clinical trials was undertaken. Relevant publications from PubMed, the Cochrane Library, and abstracts from American Society of Clinical Oncology meetings were searched. Progression-free survival (PFS), as a measure of the efficacy of treatment, was the primary outcome investigated. The pooled analysis revealed an overall significant improvement in PFS (HR = 0.44, 95 CI 0.28�0.69; p = 0.0004) with the use of EGFR TKIs in EGFR-mutated NSCLC. The data stratification per age subgroups showed that EGFR TKIs were more effective in prolonging PFS in elderly patients, with HR 0.39 (p = 0.008), in comparison with young patients (HR = 0.48; p = 0.04). The results of this study suggest that EGFR TKIs have a significant effect in slowing down diseases progression in elderly patients with advanced NSCLC, therefore representing a valid therapeutic option in this age group. © 2017, Springer International Publishing Switzerland.

Item Type: Article
Additional Information: cited By 4
Uncontrolled Keywords: afatinib; epidermal growth factor receptor; erlotinib; gefitinib; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; mutant protein; protein kinase inhibitor; protein tyrosine kinase, advanced cancer; age; aged; antineoplastic activity; cancer chemotherapy; cancer patient; cancer survival; drug efficacy; gene mutation; human; long term survival; meta analysis; monotherapy; non small cell lung cancer; overall survival; priority journal; progression free survival; Review; systematic review; antagonists and inhibitors; genetics; metabolism; non small cell lung cancer; randomized controlled trial (topic); treatment outcome, Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Mutant Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Receptor, Epidermal Growth Factor; Treatment Outcome
Subjects: WF Respiratory System
QV Pharmacology
Depositing User: eprints admin
Date Deposited: 01 Jan 2019 11:40
Last Modified: 24 Aug 2019 07:45

Actions (login required)

View Item View Item